Hunt Valley, Maryland (PRWEB) August 20, 2011
Baltimore Area Dermatologist Dr. Robert Weiss featured on TV for his work on LaViv®, a natural alternative to injectable cosmetic fillers such as Restylane®, Juvederm®, and Radiesse®.
Dr. Robert Weiss, of the Baltimore-area Maryland Laser Skin and Vein Institute, has been spending several years helping develop and test a new alternative to traditional cosmetic fillers. The procedure, LaViv, has was discussed during an interview on NBC’s WBAL-TV news.
The difference between the LaViv procedure and other, traditional cosmetic fillers is that hyaluonic acid fillers such as Restylane and Juvederm work by injecting hyaluronic acid into the skin to reduce wrinkles and lines. LaViv works by taking a sample of a patient’s own skin cells, “revving them up”, and injecting them into lines in the face, causing the skin to create its own new supply of collagen and hyaluronic acid. In some cases, the treatment regimen has improved skin tone and wrinkles for over 5 years.
The treatment is also a welcome addition to the cosmetic roster for those who are highly allergic to foreign substances; since LaViv is composed of a patient’s own stem cells, the likelihood of rejection or allergic reaction is much lower than traditional fillers can offer. And, according to Dr. Weiss, the use goes beyond simply nose-to-mouth lines. “Acne scars and fine lines [around the eyes] – it can be part of a rejuvenation program.”
Dr. Weiss has appeared on WBAL to discuss Coolsculpting® by Zeltiq®, a non-invasive liposculpture technique, and has made appearances on the Today show, Good Morning America and 20/20 to discuss skin cancer and varicose veins. The New York Times, Vogue, and Style Magazine have also consulted Dr. Weiss for information regarding dermatological procedures, including LaViv Fibrocell technology.
The Maryland Laser, Skin and Vein Institute is a cosmetically oriented dermatology practice, originated by Drs. Robert & Margaret Weiss over 20 years ago, based in Hunt Valley (Baltimore), MD. The MDLSV Institute not only treats thousands of patients per year, but is a leading clinical research facility investigating new skin treatments and devices for the purposes of FDA clearance and improving patient treatments and outcomes.
Each person’s laVív treatment is unique because it is made from their own cells. Small fibroblast samples are taken from behind the patient’s ear and sent to the Fibrocell Science lab. Over a period of approximately 90 days, hundreds of millions of fibroblasts are cultured and then frozen until needed for treatment. The recommended course of laVív administration is a series of three treatments, typically three to six weeks apart.
Additional information about laVív, including complete Prescribing Information, will be available on http://www.mylaviv.com within the coming days.
Fibrocell Science, Inc. is a cell therapy company focused on the development of autologous (personalized) cell therapies for aesthetic, medical and scientific applications. Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well its innovative cellular processing technology and manufacturing excellence. For additional information, please visit http://www.fibrocellscience.com.